OS Therapies management to attend H.C. Wainwright Global Investment ConferencePUBT·Sep 2 at 11:21 AMOSTX+3.30%
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance | OSTX Stock NewsStockTitan·Sep 2 at 03:20 AMOSTX+3.30%
Jason McCarthy Initiates Buy on OS Therapies, Citing Advancing OST-HER2 Program, Key Regulatory Catalysts, and Strengthened Cash Runway Into 2027Tip Ranks·Aug 24 at 07:05 AMOSTX+3.30%
OS Therapies Launches $75 Million ATM Program Under Sales Agreement With JefferiesTradingView·Aug 21 at 08:53 PMOSTX+3.30%JEF+1.79%
OS Therapies launches USD 75 million at-the-market equity offering via JefferiesPUBT·Aug 21 at 08:51 PMOSTX+3.30%JEF+1.79%
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates | OSTX Stock NewsStockTitan·Aug 17 at 03:40 AMOSTX+3.30%
OS Therapies Inc 2Q 2026: Net loss $8.63M, EPS $(0.20) — 10-Q SummaryTradingView·Aug 14 at 09:13 PMOSTX+3.30%
OS Therapies net loss widens to $19.03 million in FY26 first half; revenue remains no revenuePUBT·Aug 14 at 09:05 PMOSTX+3.30%
OSTX: Net loss increased to $19.0 million amid rising R&D costs and ongoing liquidity challengesQuartr·Aug 14 at 09:03 PMOSTX+3.30%
OS Therapies wins FDA Type C meeting to review 2.5-year survival data for OST-HER2 Phase 2b osteosarcoma trialPUBT·Aug 13 at 12:46 PMOSTX+3.30%
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma | OSTX Stock NewsStockTitan·Aug 13 at 04:45 AMOSTX+3.30%
OS Therapies prices up to $10 million senior secured convertible note private placementPUBT·Aug 12 at 08:56 PMOSTX+3.30%
OS Therapies agrees to repay Leonite debt in USD 1.9 million cash settlementPUBT·Aug 6 at 09:18 PMOSTX+3.30%
